Sana Biotechnology - SANA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $13.50
  • Forecasted Upside: 718.18%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.65
▲ +0.05 (3.13%)

This chart shows the closing price for SANA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sana Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SANA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SANA

Analyst Price Target is $13.50
▲ +718.18% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Sana Biotechnology in the last 3 months. The average price target is $13.50, with a high forecast of $16.00 and a low forecast of $8.00. The average price target represents a 718.18% upside from the last price of $1.65.

This chart shows the closing price for SANA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 contributing investment analysts is to moderate buy stock in Sana Biotechnology. This rating has held steady since October 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
11/5/2024HC WainwrightLower TargetBuy ➝ Buy$11.00 ➝ $8.00
11/5/2024JMP SecuritiesDowngradeOutperform ➝ Market Perform
8/9/2024CitigroupBoost TargetBuy ➝ Buy$8.00 ➝ $15.00
8/9/2024HC WainwrightLower TargetBuy ➝ Buy$12.00 ➝ $11.00
6/26/2024Rodman & RenshawInitiated CoverageBuy$16.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
3/1/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $15.00
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
1/16/2024HC WainwrightUpgradeNeutral ➝ Buy$12.00
10/12/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$9.00 ➝ $8.00
9/25/2023JMP SecuritiesInitiated CoverageOutperform$9.00
9/5/2023CitigroupInitiated CoverageBuy$8.00
8/14/2023TD CowenInitiated CoverageMarket Perform
5/2/2023HC WainwrightInitiated CoverageNeutral
3/17/2023Bank of AmericaLower Target$13.00 ➝ $11.00
1/24/2023Morgan StanleyLower TargetOverweight$15.00 ➝ $13.00
11/3/2022The Goldman Sachs GroupLower TargetNeutral$7.00 ➝ $6.00
5/17/2022Morgan StanleyLower TargetOverweight$15.00
8/6/2021The Goldman Sachs GroupLower TargetNeutral$39.00 ➝ $34.00
3/1/2021JPMorgan Chase & Co.Initiated CoverageNeutral$35.00
3/1/2021Morgan StanleyInitiated CoverageOverweight$40.00
3/1/2021The Goldman Sachs GroupInitiated CoverageNeutral$40.00
3/1/2021Bank of AmericaInitiated CoverageBuy$45.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/24/2024
  • 6 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/23/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/22/2024
  • 2 very positive mentions
  • 17 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
11/21/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/21/2024

Current Sentiment

  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Sana Biotechnology logo
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $1.65
Low: $1.55
High: $1.72

50 Day Range

MA: $2.93
Low: $1.60
High: $4.23

52 Week Range

Now: $1.65
Low: $1.55
High: $12.00

Volume

3,201,361 shs

Average Volume

2,143,796 shs

Market Capitalization

$368.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Sana Biotechnology?

The following Wall Street research analysts have issued stock ratings on Sana Biotechnology in the last year: Citigroup Inc., HC Wainwright, JMP Securities, and Rodman & Renshaw.
View the latest analyst ratings for SANA.

What is the current price target for Sana Biotechnology?

0 Wall Street analysts have set twelve-month price targets for Sana Biotechnology in the last year. Their average twelve-month price target is $13.50, suggesting a possible upside of 718.2%. Rodman & Renshaw has the highest price target set, predicting SANA will reach $16.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Sana Biotechnology in the next year.
View the latest price targets for SANA.

What is the current consensus analyst rating for Sana Biotechnology?

Sana Biotechnology currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SANA.

What other companies compete with Sana Biotechnology?

How do I contact Sana Biotechnology's investor relations team?

Sana Biotechnology's physical mailing address is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. The company's listed phone number is 206-701-7914 and its investor relations email address is [email protected]. The official website for Sana Biotechnology is sana.com. Learn More about contacing Sana Biotechnology investor relations.